Protocol Design Optimization Is Starting to Improve Clinical Study Performance, According to the Tufts Center for the Study of Drug Development
September 09, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 9, 2014) - Efforts by drug companies to streamline and improve the execution of clinical study designs -- to counter mounting costs and shorten development times...
Drug Company Collaborations to Reduce Development Risk Are Increasing, According to Tufts Center for the Study of Drug Development
August 07, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 7, 2014) - As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are...
Orphan Drug Approvals Have Increased, But High Costs Pose Challenges for Patients, According to the Tufts Center for the Study of Drug Development
July 10, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 10, 2014) - Although the pace of approvals for new orphan drugs -- medicines that treat relatively rare conditions -- have increased in the United States and Europe...
The Academy of Radiology Research Featured in Nature Biotechnology Journal
June 06, 2014 13:16 ET
|
Academy of Radiology Research
WASHINGTON, June 6, 2014 (GLOBE NEWSWIRE) -- The Academy of Radiology Research reported in the current issue of Nature Biotechnology (Volume 32, Issue 6) that patent output from the National...
ACORE Announces Submission of Comments on DOE's Biofuel Research and Development Pathways
June 02, 2014 09:37 ET
|
American Council on Renewable Energy
WASHINGTON, June 2, 2014 (GLOBE NEWSWIRE) -- Today, the American Council On Renewable Energy (ACORE) announced that it has submitted comments to the U.S. Department of Energy (DOE) which sought...
Risk-Sharing Drug Development Programs Experience Longer Development Times, According to the Tufts Center for the Study of Drug Development
May 08, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 8, 2014) - Drug development programs that involve several partners who share clinical development risks accounted for about half of all new therapeutic drug approvals...
Battelle Announces Third Annual CyberAuto Challenge
April 07, 2014 09:35 ET
|
Battelle
COLUMBUS, OH--(Marketwired - Apr 7, 2014) - Scores of students, engineers, scientists, policy leaders and white hat "hackers" will gather in Detroit this summer for the third annual Battelle...
Drug Developers Circumspect About Using Social Media in Clinical Research, According to the Tufts Center for the Study of Drug Development
March 06, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 6, 2014) - Social media is gaining ground as an important tool to improve the clinical research process through more effective engagement of patient communities, but...
New ISR Report Identifies Why Forest Labs' Pipeline Is a Hot Topic
February 25, 2014 14:40 ET
|
Industry Standard Research
CARY, NC--(Marketwired - Feb 25, 2014) - Industry Standard Research (ISR) has announced the availability of a new report titled "Forest Labs Clinical Development Profile." This report provides...
New Breakthrough Therapy Designation Has Potential to Shorten Development Time Considerably, According to the Tufts Center for the Study of Drug Development
January 23, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 23, 2014) - The recently launched Breakthrough Therapy Designation (BTD) program in the United States, aimed at expediting development and review of drugs intended to...